BidaskClub upgraded shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) from a sell rating to a hold rating in a research note released on Saturday.

A number of other analysts have also commented on the stock. TheStreet raised shares of Taro Pharmaceutical Industries from a c rating to a b- rating in a research report on Thursday, July 20th. Credit Suisse Group lowered shares of Taro Pharmaceutical Industries from an outperform rating to a neutral rating in a research report on Tuesday, May 23rd.

Taro Pharmaceutical Industries (NYSE TARO) opened at 104.44 on Friday. The company has a market cap of $4.23 billion, a P/E ratio of 10.64 and a beta of 0.65. The stock’s 50 day moving average is $106.58 and its 200-day moving average is $112.09. Taro Pharmaceutical Industries has a 12-month low of $92.28 and a 12-month high of $125.87.

TRADEMARK VIOLATION WARNING: “BidaskClub Upgrades Taro Pharmaceutical Industries Ltd. (TARO) to Hold” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/bidaskclub-upgrades-taro-pharmaceutical-industries-ltd-taro-to-hold/1557797.html.

Several hedge funds have recently made changes to their positions in TARO. FMR LLC lifted its position in shares of Taro Pharmaceutical Industries by 42.2% in the second quarter. FMR LLC now owns 466,590 shares of the company’s stock worth $52,286,000 after purchasing an additional 138,353 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Taro Pharmaceutical Industries by 35.3% in the second quarter. Dimensional Fund Advisors LP now owns 178,392 shares of the company’s stock worth $19,991,000 after purchasing an additional 46,570 shares in the last quarter. River Road Asset Management LLC lifted its position in shares of Taro Pharmaceutical Industries by 33.3% in the second quarter. River Road Asset Management LLC now owns 65,470 shares of the company’s stock worth $7,337,000 after purchasing an additional 16,350 shares in the last quarter. Aperio Group LLC lifted its position in shares of Taro Pharmaceutical Industries by 46.9% in the second quarter. Aperio Group LLC now owns 50,826 shares of the company’s stock worth $5,696,000 after purchasing an additional 16,233 shares in the last quarter. Finally, AHL Partners LLP lifted its position in shares of Taro Pharmaceutical Industries by 35.2% in the second quarter. AHL Partners LLP now owns 26,604 shares of the company’s stock worth $2,981,000 after purchasing an additional 6,923 shares in the last quarter. 14.24% of the stock is currently owned by institutional investors and hedge funds.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.